Keywords
Desensitization
Basophil activation test
Skin testing
Ixekizumab
Abstract
Background: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more unusual.
Case report: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.
Conclusion: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.
Keywords: Hypersensitivity; Ixekizumab; Systemic reaction; Skin test; Desensitization protocol.
References
1. Pharmacoeconomic Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 May. PMID: 33237678.
2. Griffiths CEM, Gooderham M, Colombel JF, Terui T, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatol Ther (Heidelb) 2022; 12 (6): 1431-1446. doi: 10.1007/s13555-022-00743-9.
3. Muraro A, Worm M, Alviani C, Cardona V, et al; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy 2022; 77 (2): 357-377. doi: 10.1111/all.15032.
4. de la Varga-Martínez R, Gutiérrez-Fernández D, Foncubierta-Fernández A, Andrés-García JA, et al. Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test. Allergol Int 2017; 66 (2): 357-359. doi: 10.1016/j.alit.2016.09.002.
5. ALMuhizi F, De Las Vecillas-Sanchez L, Gilbert L, Copaescu AM, et al. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review. Clin Rev Allergy Immunol 2022; 62 (3): 534-547. doi: 10.1007/s12016-022-08932-2.
6. Jimenez RB, Vera DG, Rivera-Díaz R, Cortijo-Cascajares S, et al. Successful subcutaneous desensitization in a patient with allergy to ixekizumab. J Allergy Clin Immunol Pract 2018; 6 (5): 1761-1762. doi: 10.1016/j.jaip.2017.12.036.
7. Bavbek S, Ataman Ş, Akıncı A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015; 3 (4): 629-32. doi: 10.1016/j.jaip.2015.01.009.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México